An advantage of PRRT treatment with 177Lu-DOTA-AE105 is that it is based on the same uPAR binding peptide, AE105, as 68Ga-NOTA-AE105 implying the use of uPAR-PET as a companion diagnostic for treatment planning, monitoring, and dosimetry estimation in a uPAR-PRRT theragnostic approach in gliomas. The gene discussed is PLAUR; the disease is central nervous system cancer.